Table: q1_q4_2021_prescription_drug_wac_increases , manufacturer_name like I*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
Rx0000040	Ingenus Pharmaceuticals, LLC	03/31/2021	50742051530	Nitro-Dur Patch 0.3mg/hr 30 ct	02/15/2021	235.52	1177.58	None	Single Source Drug	6255	None	Increased overhead, expenses, and distribution costs causing need for price increase so as not to experience service disruption.	None	No changes made	None	08/31/2017	USPharma	2000000	None	The acquisition price provided was for the acquisition of the Nitro-Dur product line from USPharma and is not a SKU specific figure	316.92	157.50	2017	316.92	None	Patent expiration date: as this product is pre-patent, we do not have a patent expiration date to provide Year Introduced to Market: only the 0.3mg sold in 2017, the rest of the SKUs were first sold in 2018. However, we loaded all SKUs to the Gold Standard with 2017 effective dates. Therefore, we have listed 2017 as the introduction year
Rx0000040	Ingenus Pharmaceuticals, LLC	03/31/2021	50742051830	Nitro-Dur Patch 0.8mg/hr 30 ct	02/15/2021	255.44	1277.13	None	Single Source Drug	2585	None	Increased overhead, expenses, and distribution costs causing need for price increase so as not to experience service disruption.	None	No changes made	None	08/13/2017	USPharma	2000000	None	The acquisition price provided was for the acquisition of the Nitro-Dur product line from USPharma and is not a SKU specific figure	343.71	170.70	2017	343.71	None	Patent expiration date: as this product is pre-patent, we do not have a patent expiration date to provide Year Introduced to Market: only the 0.3mg sold in 2017, the rest of the SKUs were first sold in 2018. However, we loaded all SKUs to the Gold Standard with 2017 effective dates. Therefore, we have listed 2017 as the introduction year
Rx0000287	Insmed Incorporated	03/31/2021	71558059028	AMIKACIN LIPOSOME INHALATION SUSPENSION EQ 590MG BASE/8.4ML	01/01/2021	755.69	12381.68	05/15/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Product developed in-house
Rx0000084	Ipsen Biopharmaceuticals, Inc.	03/31/2021	15054104005	Drug product name: Increlex. Drug product strength: 10 mg/ml. Drug product dosage form: vial. Drug product package size: 4ml.	01/12/2021	221.00	5127.00	03/11/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book. The product was not acquired by Ipsen within the previous five years.
Rx0000084	Ipsen Biopharmaceuticals, Inc.	03/31/2021	15054004301	Drug product name: Onivyde. Drug product strength: 43 mg/10 ml (4.3 mg/ml). Drug product dosage form: vial. Drug product package size: 10ml.	01/12/2021	106.00	2472.00	10/15/2036	Single Source Drug	None	1	None	1	None	1	04/03/2017	Merrimack Pharmaceuticals	None	1	For purposes of 22 CCR § 96070(b)(12)(c) (requirement to report the purchase price of the relevant drug, if the drug was acquired by the manufacturer within the previous five years), Ipsen purchased the global oncology assets of Merrimack Pharmaceuticals in April 2017, including Onivyde. The purchase price of the drug product (as Ipsen understands that data element) is not in the public domain or otherwise publicly available. However, information regarding Ipsen’s purchase of the assets from Merrimack Pharmaceuticals is available on p. 97, Note 12.1.1 of section 3.2.5, of the Registration Document located at: https://www.ipsen.com/websites/Ipsen_Online/wp-content/uploads/2018/03/15164935/IPSEN_DDR_2017_VA_complet_clean-003.pdf	1652.40	None	2015	1620.00	None	The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book. The information provided in response to 22 CCR § 96070(b)(11) contains price increases for the drug product when the NDC for the product was 69171-0398-01
Rx0000084	Ipsen Biopharmaceuticals, Inc.	03/31/2021	15054112004	Drug product name: Somatuline Depot - New NDC. Drug product strength: 120 mg/0.5 ml. Drug product dosage form: syringe. Drug product package size: .50 ml.	01/12/2021	394.00	9150.00	03/08/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This NDC was launched on September 1, 2019 and will replace NDC 15054112003. The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book.
Rx0000084	Ipsen Biopharmaceuticals, Inc.	03/31/2021	15054106004	Drug product name: Somatuline Depot - New NDC. Drug product strength: 60 mg/0.2 ml. Drug product dosage form: syringe. Drug product package size: .20 ml.	01/12/2021	251.00	5826.00	03/08/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This NDC was launched on September 1, 2019 and will replace NDC 15054106003. The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book.
Rx0000084	Ipsen Biopharmaceuticals, Inc.	03/31/2021	15054109004	Drug product name: Somatuline Depot - New NDC. Drug product strength: 90 mg/0.3 ml. Drug product dosage form: syringe. Drug product package size: .30 ml.	01/12/2021	334.00	7759.00	03/08/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This NDC was launched on September 1, 2019 and will replace NDC 15054109003. The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book.
Rx0000084	Ipsen Biopharmaceuticals, Inc.	03/31/2021	15054112003	Drug product name: Somatuline Depot - Old NDC. Drug product strength: 120 mg/0.5 ml. Drug product dosage form: syringe. Drug product package size: .50 ml.	01/12/2021	394.00	9150.00	03/08/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book. The product was not acquired by Ipsen within the previous five years.
Rx0000084	Ipsen Biopharmaceuticals, Inc.	03/31/2021	15054109003	Drug product name: Somatuline Depot - Old NDC. Drug product strength: 90 mg/0.3 ml. Drug product dosage form: syringe. Drug product package size: .30 ml.	01/12/2021	334.00	7759.00	03/08/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book. The product was not acquired by Ipsen within the previous five years.
Rx0000084	Ipsen Biopharmaceuticals, Inc.	03/31/2021	15054106003	Drug product name: Somatuline Depot - Old NDC. Drug product strength: 60 mg/0.2 ml. Drug product dosage form: syringe. Drug product package size: .20 ml.	01/12/2021	251.00	5826.00	03/08/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book. The product was not acquired by Ipsen within the previous five years.